Citations

Showing 10 of 108094 citations.

324 Sensitizing poorly differentiated thyroid cancers to TSHR-CART cell therapy with MEK inhibitors
Copland, John A. , Schick, Kendall J. , Gleba, Justyna, Miller, James E. , MIller, Erin, Demirer, Aylin Alasonyalılar , Tapper, Erin E. , Stewart, Carli M. , Ogbodo, Ekene J. , Evandro, Bezerra, Georges, Mer, Gloria, Olivier, Qui, Yushi, Smallridge, Robert C., Trynda, Justyna , Gleba, Justyna , Huynh, Truc, Sakemura, Reona , Siegler, Elizabeth L. , Cox, Michelle J. , Stewart, Carli , Can, Ismail, Roman, Claudia Manriquez , Gaofeng, Cui, Zubair, Abba C. , Tun, Han W. , Kenderian, Saad S.

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: A340-A341

10.1136/jitc-2022-sitc2022.0324 Get It

229 A2B530, an autologous CEA-directed Tmod T-cell therapy with an inhibitory receptor gated by HLA-A*02 to target colorectal, pancreatic, and lung cancer
Hecht, J. Randolph, Sandberg, Mark, Wang, Xueyin , Martin, Aaron, Nampe, Daniel , Gabrelow, Grant B. , Li, Chuck, McElvain, Michele , Lee, Wen-Hua , Shafaattalab, Sanam , Martire, Sara , Fisher, F. , Ando, Yuta, Liu, Edwin , Ju, David, Hsin, Jing-Ping, Zampieri, Alexandre, Morelli, Maria Pia , Welling, Theodore H., Patel, Sandip Pravin , Welch, John S. , Go, William Y., Mardiros, Armen, Maloney, David G. , Wong, Lu-Min, Xu, Han , Molina, Julian R. , Ando, Yuta, Liu, Edwin, Ju, David, Simeone, Diane M. , Kopetz, Scott , Borad, Mitesh J. , Garon, Edward B. , Kirtane, Kedar , Locke, Frederick L. , Ng, Eric, Kamb, Alexander

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: A242-A242

10.1136/jitc-2022-sitc2022.0229 Get It

140 Assessment of differences in tumor mutational burden identified on liquid biopsy in 16,870 patients newly diagnosed with metastatic cancer
Kwon, Eugene D., Stish, Bradley J. , Boorjian, Stephen A. , Tollefson, Matthew K. , Britton, Cameron J. , Mahmoud, Ahmed , Thompson, Angela , Drusbosky, Leylah , Mahmoud, Ahmed M , Childs, Daniel S. , Barnett, Reagan M. , Bucheit, Leslie

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: A153-A153

10.1136/jitc-2022-sitc2022.0140 Get It

109 Quantitative spatial assessment of the tumor-immune microenvironment in the metastatic melanoma lymph node
Maus, Rachel L.G., Moore, Raymond C., Leontovich, Alexey A. , Dona, Chathu, Dicke, Betty A., Moore, Raymond, Fogarty, Zachary C. , Guo, Ruifeng, Tekin, Burak , Schimke, Jill M. , Chen, Benjamin K. , Markovic, Svetomir N.

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: A119-A119

10.1136/jitc-2022-sitc2022.0109 Get It

77 An NGS assay to identify HLA loss of heterozygosity for future CEA and MSLN logic-gated CAR-T solid tumor protocols designed for reduced on-target, off-tumor toxicity
Morelli, Maria Pia , Molina, Julian R. , Hecht, J. Randolph, Welling, Theodore H., Mardiros, Armen, Wang, Xueyin , Danek, Tyler , Gallagher, Shannon , Lozac’hmeur, Ariane, Beutner, Karl R., Welch, John S. , Maloney, David G. , Go, William Y., Patel, Sandip Pravin , Kopetz, Scott , Simeone, Diane M. , Kirtane, Kedar , Borad, Mitesh J. , Garon, Edward B. , Ng, Eric, Gallagher, Shannon

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: A83-A83

10.1136/jitc-2022-sitc2022.0077 Get It

Incidental Coronary Artery Calcium: Opportunistic Screening of Previous Nongated Chest Computed Tomography Scans to Improve Statin Rates (NOTIFY-1 Project)
Sandhu, Alexander T. , Rodríguez, Fátima , Ngo, Summer , Patel, Bhavik N. , Mastrodicasa, Domenico , Eng, David , Khandwala, Nishith , Balla, Sujana , Sousa, Doug, Maron, David J. , Maron, David J

Mayo Clinic

Circulation | November 7, 2022 | Volume: 147 | Issue: 9 | Pages: 703-714

10.1161/circulationaha.122.062746 | PMID 36342823 Get It

Background: Coronary artery calcium (CAC) can be identified on nongated chest computed tomography (CT) scans, but this finding is not consistently incorporated into care. A deep learning algorithm enables opportunistic CAC screening of nongated chest CT scans. Our objective was to evaluate the effect of notifying clinicians and patients of incidental CAC on statin initiation. Methods: NOTIFY-1 (Incidental Coronary Calcification Quality Improvement Project) was a randomized quality improvement project in the Stanford Health Care System. Patients without known atherosclerotic cardiovascular disease or a previous statin prescription were screened for CAC on a previous nongated chest CT scan from 2014 to 2019 using a validated deep learning algorithm with radiologist confirmation. Patients with incidental CAC were randomly assigned to notification of the primary care clinician and patient versus usual care. Notification included a patient-specific image of CAC and guideline recommendations regarding statin use. The primary outcome was statin prescription within 6 months. Results: Among 2113 patients who met initial clinical inclusion criteria, CAC was identified by the algorithm in 424 patients. After chart review and additional exclusions were made, a radiologist confirmed CAC among 173 of 194 patients (89.2%) who were randomly assigned to notification or usual care. At 6 months, the statin prescription rate was 51.2% (44/86) in the notification arm versus 6.9% (6/87) with usual care ( P <0.001). There was also more coronary artery disease testing in the notification arm (15.1% [13/86] versus 2.3% [2/87]; P =0.008). Conclusions: Opportunistic CAC screening of previous nongated chest CT scans followed by clinician and patient notification led to a significant increase in statin prescriptions. Further research is needed to determine whether this approach can reduce atherosclerotic cardiovascular disease events. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04789278.
Overcoming the Interobserver Variability in Lung Adenocarcinoma Subtyping: A Clustering Approach to Establish a Ground Truth for Downstream Applications
Lami, Kris , Bychkov, Andrey , Matsumoto, Keitaro , Attanoos, Richard , English, John C. , Kashima, Yukio, Larsen, Brandon T. , Marchevsky, Alberto M. , Miyazaki, Takuro , Morimoto, Shimpei , Roden, Anja C. , Schneider, Frank , Soshi, Mano, Tanaka, Tomonori , Nagayasu, Takeshi , Bychkov, Andrey , Berezowska, Sabina , Brčić, Luka , Fabro, Alexandre Todorovic , Ishida, Kaori, Smith, Maxwell L. , Tabata, Kazuhiro , Takano, Angela Maria , Tanaka, Kei E. I. , Tsuchiya, Tomoshi , Fukuoka, Junya

Mayo Clinic

Archives of Pathology & Laboratory Medicine | November 7, 2022 | Volume: 147 | Issue: 8 | Pages: 885-895

10.5858/arpa.2022-0051-oa | PMID 36343368 Get It

Context.— The accurate identification of different lung adenocarcinoma histologic subtypes is important for determining prognosis but can be challenging because of overlaps in the diagnostic features, leading to considerable interobserver variability. Objective.— To provide an overview of the diagnostic agreement for lung adenocarcinoma subtypes among pathologists and to create a ground truth using the clustering approach for downstream computational applications. Design.— Three sets of lung adenocarcinoma histologic images with different evaluation levels (small patches, areas with relatively uniform histology, and whole slide images) were reviewed by 17 international expert lung pathologists and 1 pathologist in training. Each image was classified into one or several lung adenocarcinoma subtypes. Results.— Among the 4702 patches of the first set, 1742 (37%) had an overall consensus among all pathologists. The overall Fleiss κ score for the agreement of all subtypes was 0.58. Using cluster analysis, pathologists were hierarchically grouped into 2 clusters, with κ scores of 0.588 and 0.563 in clusters 1 and 2, respectively. Similar results were obtained for the second and third sets, with fair-to-moderate agreements. Patches from the first 2 sets that obtained the consensus of the 18 pathologists were retrieved to form consensus patches and were regarded as the ground truth of lung adenocarcinoma subtypes. Conclusions.— Our observations highlight discrepancies among experts when assessing lung adenocarcinoma subtypes. However, a subsequent number of consensus patches could be retrieved from each cluster, which can be used as ground truth for the downstream computational pathology applications, with minimal influence from interobserver variability.
Examining the Impact of Breast Augmentation vs Hormone Therapy on Chest Femininity of Transgender Women
Zhu, Agnes , Callori, Steven , Boonipat, Thanapoom , Hebel, Nathan , Jorge-Martinez, Jorys

Mayo Clinic

Aesthetic Surgery Journal | November 7, 2022 | Volume: 43 | Issue: 2 | Pages: NP114-NP121

10.1093/asj/sjac288 | PMID 36342750 Get It

Abstract Background For transgender women, there is often the innate assumption that surgical breast augmentation will increase perceived chest femininity beyond hormone therapy alone. Objectives This study aimed to evaluate whether lay individuals found surgically augmented breasts more feminine than breast development from hormone replacement therapy alone in transgender patients. Methods We obtained preoperative (maximal breast growth on hormone therapy) and postoperative chest (after primary augmentation) images of 22 transgender patients, and age- and BMI-matched cisgender male (n = 17) and female (n = 21) control patients. Survey respondents (n = 271) rated each image on a scale of 1 (very feminine) to 5 (very masculine). Results were compared by survey respondent gender identity and sexual orientation. Results There was a significant difference in mean femininity score between all image types. Mean score for transgender patients fell by 0.478 points after surgery (P &lt; .0001). Subgroup analysis looking at transgender participants revealed the same significance trend postoperatively. Transgender respondents also found no difference in femininity between female controls and postoperative transgender patients (P = .132). We also compared mean femininity scores across 4 self-identified respondent subgroups: cisgender and heterosexual, cisgender and lesbian, gay, or bisexual (LGB), transgender and heterosexual, and transgender and LGB. The cisgender and heterosexual subgroup rated the postoperative transgender patients more feminine than any of the other respondent subgroups (LGB P &lt; .001, transgender and LGB P &lt; .001, transgender only P = .018). Conclusions This study shows that breast augmentation significantly increased the perception of femininity. Furthermore, gender identity and sexual orientation are important in how lay persons perceive transgender patients. Level of Evidence: 4
Daily Low-Dose Aspirin and Risk of Serious Falls and Fractures in Healthy Older People
Morello, Renata , Thảo, Lê Thị Phương , Sanders, Kerrie M. , Pasco, Julie A. , Ebeling, Peter R. , Woods, Robyn L. , Wolfe, Rory , Hussain, Sultana Monira , Ronaldson, Kathlyn J. , Williamson, Jeff D. , Ebeling, Peter R , Barker, Anna , Seeman, Ego , Ward, Stéphanie , Cumming, Robert G. , Khosla, Sundeep , Newman, Anne B. , McNeil, John J.

Mayo Clinic

JAMA Internal Medicine | November 7, 2022 | Volume: 182 | Issue: 12 | Pages: 1289

10.1001/jamainternmed.2022.5028 | PMID 36342703 Get It

ImportanceFalls and fractures are frequent and deleterious to the health of older people. Aspirin has been reported to reduce bone fragility and slow bone loss.ObjectiveTo determine if daily low-dose aspirin (100 mg) reduces the risk of fractures or serious falls (fall-related hospital presentations) in healthy older men and women.Design, Setting, and ParticipantsThis substudy of a double-blind, randomized, placebo-controlled trial studied older adult men and women in 16 major sites across southeastern Australia. The ASPREE-FRACTURE substudy was conducted as part of the Australian component of the ASPREE trial. Between 2010 and 2014 healthy (free of cardiovascular disease, dementia or physical disability), community-dwelling volunteers aged 70 years or older were recruited to participate in the ASPREE trial. Potentially eligible participants were identified by medical practitioners and trial personnel and were then sent a letter of invitation to participate. Interested participants were screened for suitability. Eligible participants with medical practitioner authorization and adherent to a 4-week run-in medication trial were randomized. Data were analyzed from October 17, 2019, to August 31, 2022.InterventionsParticipants in the intervention group received a daily dose of oral 100 mg enteric-coated (low-dose) aspirin. The control group received a daily identical enteric-coated placebo tablet.Main Outcomes and MeasuresThe primary outcome of ASPREE-FRACTURE was the occurrence of any fracture. The secondary outcome was serious fall resulting in hospital presentation.ResultsIn total, 16 703 people with a median (IQR) age of 74 (72-78) years were recruited, and 9179 (55.0%) were women. There were 8322 intervention participants and 8381 control participants included in the primary and secondary outcome analysis of 2865 fractures and 1688 serious falls over the median follow-up of 4.6 years. While there was no difference in the risk of first fracture between the intervention and control participants (hazard ratio, 0.97; 95% CI, 0.87-1.06; P = .50), aspirin was associated with a higher risk of serious falls (total falls 884 vs 804; incidence rate ratio, 1.17; 95% CI, 1.03-1.33; P = .01). Results remained unchanged in analyses that adjusted for covariates known to influence fracture and fall risk.Conclusions and RelevanceIn this substudy of a randomized clinical trial, the failure of low-dose aspirin to reduce the risk of fractures while increasing the risk of serious falls adds to evidence that this agent provides little favorable benefit in a healthy, White older adult population.Trial RegistrationThis substudy is registered with the Australian New Zealand Clinical Trials Registry (ACTRN12615000347561).